eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2016
vol. 67
 
Share:
Share:
more
 
 
abstract:
Original paper

A rare CD5-positive subgroup of diffuse large B-cell lymphoma – clinical, morphological and immunophenotypic features in Polish patients

Nina Woźnialis
1
,
Beata Gierej
1, 2
,
Lidia Popławska
3
,
Mateusz Ziarkiewicz
4
,
Elżbieta Kulczycka
1
,
Bogna Ziarkiewicz-Wróblewska
1, 2

1.
Department of Pathology and Laboratory Diagnostics, Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland
2.
Department of Pathology, Center for Biostructure Research, Medical University of Warsaw, Warsaw, Poland
3.
Department of Lymphoid Malignancies, Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland
4.
Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
Pol J Pathol 2016; 67 (3): 235-243
Online publish date: 2016/11/25
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
PlumX metrics:
The aim of the study was to assess the incidence of CD5-positive diffuse large B-cell lymphoma (DLBCL) in the Polish population and to describe its morphologic and clinical characteristics. The study included 36 patients with CD5-positive DLBCL, diagnosed and treated in the Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland and the Medical University of Warsaw, Poland in the years 2002-2013. The control group consisted of 28 patients with CD5-negative DLBCL. CD5-positive DLBCL accounted for 6.26% of all DLBCL cases diagnosed in the Maria Skłodowska-Curie Institute and Oncology Centre in the years 2008-2012. The incidence is comparable to other European countries, lower than noted in Japan and higher than in the US. Patients with CD5-positive DLBCL, in comparison to the CD5-negative group, were characterized by: (1) older age (≥ 60 vs. younger) and worse general status (ECOG ≥ 2 vs. < 2), (2) lower frequency of complete remission (CR), (3) higher expression of unfavorable prognostic factors (BCL2, FOXP1, CD44) and MMP-9, and (4) lower expression of favorable prognostic factors (CD30, cyclin D1, cyclin D3) and TIMP-2.
keywords:

NHL, CD5-positive DLBCL, prognostic factors

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.